About C-terminal-binding protein 2
C-terminal-binding protein 2 (CTBP2) is a protein
from Homo sapiens identified by UniProt accession
P56545, 445 residues long.
MolForge cross-references it against 0 known binders and
171 disease associations.
Target properties
| Protein name | C-terminal-binding protein 2 |
| UniProt accession | P56545 |
| Gene | CTBP2 |
| Organism | Homo sapiens |
| Length | 445 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (171)
Diseases linked to this target (Open Targets).
- age at menarche · score 0.45
- erythrocyte count · score 0.42
- diet measurement · score 0.41
- cortical surface area measurement · score 0.40
- neuroimaging measurement · score 0.39
- body mass index · score 0.39
- sensorineural hearing loss · score 0.39
- hearing loss · score 0.39
- age-related hearing impairment · score 0.39
- chronotype measurement · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P56545-F1 | alphafold | PREDICTED | 83.36 | — |
Amino-acid sequence (445 residues)
MALVDKHKVK RQRLDRICEG IRPQIMNGPL HPRPLVALLD GRDCTVEMPI LKDLATVAFC DAQSTQEIHE KVLNEAVGAM MYHTITLTRE DLEKFKALRV IVRIGSGYDN VDIKAAGELG IAVCNIPSAA VEETADSTIC HILNLYRRNT WLYQALREGT RVQSVEQIRE VASGAARIRG ETLGLIGFGR TGQAVAVRAK AFGFSVIFYD PYLQDGIERS LGVQRVYTLQ DLLYQSDCVS LHCNLNEHNH HLINDFTIKQ MRQGAFLVNA ARGGLVDEKA LAQALKEGRI RGAALDVHES EPFSFAQGPL KDAPNLICTP HTAWYSEQAS LEMREAAATE IRRAITGRIP ESLRNCVNKE FFVTSAPWSV IDQQAIHPEL NGATYRYPPG IVGVAPGGLP AAMEGIIPGG IPVTHNLPTV AHPSQAPSPN QPTKHGDNRE HPNEQ
Explore C-terminal-binding protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets